Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2022 Filed Dec 9, 2022 21:07 UTC |
KELER TIBOREXECUTIVE VP & CSO
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 16,860 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-22-012301 · form4-12092022_091203.xml · derivative · entry 3 KELER TIBOR · CIK 0001429931 · EXECUTIVE VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,140 Underlying: Common Stock · 16,860 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:07 UTC |
KELER TIBOREXECUTIVE VP & CSO
|
SaleCommon Stock, par value $0.001 per share | 16,860 | $36.93 | $622,611.14 |
DisclosureSEC source: 0001415889-22-012301 · form4-12092022_091203.xml · nonDerivative · entry 2 KELER TIBOR · CIK 0001429931 · EXECUTIVE VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,357 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $37.28 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:07 UTC |
KELER TIBOREXECUTIVE VP & CSO
|
Exercise / conversionCommon Stock, par value $0.001 per share | 16,860 | $2.78 | $46,870.80 |
DisclosureSEC source: 0001415889-22-012301 · form4-12092022_091203.xml · nonDerivative · entry 1 KELER TIBOR · CIK 0001429931 · EXECUTIVE VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 20:06 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
Exercise / conversionIncentive Stock Option · Derivative | 1,355 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-22-008896 · form4-08192022_010836.xml · derivative · entry 6 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,103 Underlying: Common Stock · 1,355 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 20:06 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
SaleCommon Stock | 1,355 | $36.38 | $49,289.07 |
DisclosureSEC source: 0001415889-22-008896 · form4-08192022_010836.xml · nonDerivative · entry 4 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.65 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 20:06 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
Exercise / conversionCommon Stock | 1,355 | $9.02 | $12,217.36 |
DisclosureSEC source: 0001415889-22-008896 · form4-08192022_010836.xml · nonDerivative · entry 3 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
Exercise / conversionIncentive Stock Option · Derivative | 31,312 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-22-008896 · form4-08192022_010836.xml · derivative · entry 5 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,750 Underlying: Common Stock · 31,312 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
SaleCommon Stock | 31,312 | $36.73 | $1,150,221.27 |
DisclosureSEC source: 0001415889-22-008896 · form4-08192022_010836.xml · nonDerivative · entry 2 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.54 to $37.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
Exercise / conversionCommon Stock | 31,312 | $2.78 | $87,047.36 |
DisclosureSEC source: 0001415889-22-008896 · form4-08192022_010836.xml · nonDerivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 876 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
Exercise / conversionIncentive Stock Option · Derivative | 45,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · derivative · entry 5 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 45,000 shares Expires 2029-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested on July 8, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
Exercise / conversionIncentive Stock Option · Derivative | 19,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · derivative · entry 4 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,400 Underlying: Common Stock · 19,000 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
Exercise / conversionCommon Stock | 45,000 | $2.71 | $121,950.00 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · nonDerivative · entry 3 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
SaleCommon Stock | 19,000 | $37.30 | $708,715.20 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · nonDerivative · entry 2 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,115 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.30 to $37.35 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
Exercise / conversionCommon Stock | 19,000 | $10.38 | $197,220.00 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
Exercise / conversionIncentive Stock Option · Derivative | 45,000 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · derivative · entry 5 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,665 Underlying: Common Stock · 45,000 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019. F5 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. F2 · balance_after: This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
Exercise / conversionIncentive Stock Option · Derivative | 75,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · derivative · entry 4 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
SaleCommon Stock | 120,000 | $37.66 | $4,519,572.00 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · nonDerivative · entry 3 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,692 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.39 to $37.95 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 45,000 | $9.02 | $405,742.50 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · nonDerivative · entry 2 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 75,000 | $2.78 | $208,500.00 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · nonDerivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 461 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
Exercise / conversionIncentive Stock Option · Derivative | 15,328 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-22-008767 · form4-08172022_010827.xml · derivative · entry 3 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,672 Underlying: Common Stock · 15,328 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
SaleCommon Stock | 15,328 | $37.71 | $578,048.00 |
DisclosureSEC source: 0001415889-22-008767 · form4-08172022_010827.xml · nonDerivative · entry 2 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.35 to $38.31 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
Exercise / conversionCommon Stock | 15,328 | $10.38 | $159,104.64 |
DisclosureSEC source: 0001415889-22-008767 · form4-08172022_010827.xml · nonDerivative · entry 1 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 13,671 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · derivative · entry 10 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,750 Underlying: Common Stock · 13,671 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 3,876 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · derivative · entry 9 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,201 Underlying: Common Stock · 3,876 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
SaleCommon Stock | 1,221 | $34.62 | $42,271.75 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · nonDerivative · entry 7 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,378 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.31 to $34.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
SaleCommon Stock | 2,065 | $35.38 | $73,052.68 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · nonDerivative · entry 6 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,599 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.82 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
SaleCommon Stock | 14,261 | $36.76 | $524,304.24 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · nonDerivative · entry 5 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,664 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.23 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionCommon Stock | 13,671 | $2.78 | $38,005.38 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · nonDerivative · entry 4 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionCommon Stock | 3,876 | $9.02 | $34,947.95 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · nonDerivative · entry 3 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,453 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · derivative · entry 8 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,077 Underlying: Common Stock · 2,453 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
SaleCommon Stock | 2,453 | $37.04 | $90,856.42 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · nonDerivative · entry 2 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,378 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.26 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 20:16 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionCommon Stock | 2,453 | $9.02 | $22,117.47 |
DisclosureSEC source: 0001415889-22-008608 · form4-08152022_010833.xml · nonDerivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:19 UTC |
Wright Richard M.SR. VP & CCO
|
GrantIncentive Stock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006733 · form4-06172022_010604.xml · derivative · entry 1 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:18 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
GrantIncentive Stock Option (right to buy) · Derivative | 73,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006732 · form4-06172022_010617.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:17 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
GrantIncentive Stock Option (right to buy) · Derivative | 73,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006731 · form4-06172022_010609.xml · derivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:16 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
GrantIncentive Stock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006728 · form4-06172022_010602.xml · derivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:15 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
GrantIncentive Stock Option (right to buy) · Derivative | 76,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006726 · form4-06172022_010610.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:14 UTC |
Crowley ElizabethSR. VP &CPDO
|
GrantIncentive Stock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006722 · form4-06172022_010627.xml · derivative · entry 1 Crowley Elizabeth · CIK 0001681854 · SR. VP &CPDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:13 UTC |
Martin Samuel BatesSVP AND CFO
|
GrantIncentive Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006718 · form4-06172022_010626.xml · derivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:12 UTC |
PEPIN RONALDSR. VP & CBO
|
GrantIncentive Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006716 · form4-06172022_010613.xml · derivative · entry 1 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:11 UTC |
KELER TIBOREXECUTIVE VP & CSO
|
GrantIncentive Stock Option (right to buy) · Derivative | 91,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006712 · form4-06172022_010651.xml · derivative · entry 1 KELER TIBOR · CIK 0001429931 · EXECUTIVE VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:10 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006709 · form4-06172022_010652.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:09 UTC |
PENNER HARRY JRDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006708 · form4-06172022_010605.xml · derivative · entry 1 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:08 UTC |
CONRAD HERBERT JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006705 · form4-06172022_010604.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:07 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006700 · form4-06172022_010653.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:06 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006696 · form4-06172022_010659.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:05 UTC |
Cohen CherylDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001493152-22-017153 · ownership.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Stock · 27,200 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: One third vests on the first, second and third anniversaries of the date of grant. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:05 UTC |
NEIL GARRY ARTHURDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001493152-22-017154 · ownership.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Stock · 27,200 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: One third vests on the first, second and third anniversaries of the date of grant. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:05 UTC |
Shoos Karen L.Director
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006694 · form4-06172022_010651.xml · derivative · entry 1 Shoos Karen L. · CIK 0001255681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:02 UTC |
Martin Samuel BatesSVP and CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-21-011251 · edgar.xml · derivative · entry 5 Martin Samuel Bates · CIK 0001709024 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,421 Underlying: Common Stock · 3,750 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.